 RESEARCH TRIANGLE PARK, N.C., May 12, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency MHRA has granted marketing authorization for oral, once-daily ORLADEYOTM berotralstat for the routine prevention of recurrent hereditary angioedema HAE attacks in HAE patients 12 years and older. 